Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II Clinical Trial Evaluating Combination of Investigational Oral Candidates MK-5172 and Daclatasvir for Chronic Hepatitis C

Dateline City: 

WHITEHOUSE STATION, N.J.

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK) today announced it has entered into a non-exclusive
agreement with Bristol-Myers Squibb to conduct a Phase II clinical trial
to evaluate the safety and efficacy of a once-daily oral combination
regimen consisting of Bristol-Myers Squibb’s investigational NS5A
replication complex inhibitor daclatasvir and Merck's investigational
NS3/4A protease inhibitor MK-5172 for the treatment of chronic hepatitis
C virus (HCV) infection, genotype 1.

Language: 

English

Contact HTML: 

MerckMedia:Caroline Lappetito, [phone]orInvestor:Carol Ferguson, [phone]Justin Holko, [phone]

Ticker Slug: 

Ticker: MRK Exchange: NYSE

read more

Source: Merck.com - Research and Development News - April 22, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Source Type: news